Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study

被引：0

作者：

Poewe, W. ^{[1
]}

Stocchi, F. ^{[2
]}

Sopromadze, S. ^{[3
]}

Adar, L. ^{[3
]}

Sasson, N. ^{[3
]}

Yardeni, T. ^{[3
]}

Giladi, N. ^{[4
]}

机构：

[1] Med Univ Innsbruck, Innsbruck, Austria

[2] Univ & Inst Res & Med Care IRCCS San Raffaele, Rome, Italy

[3] NeuroDerm, Rehovot, Israel

[4] Tel Aviv Univ, Neurol Inst, Tel Aviv Med Ctr, Sackler Sch Med,Sagol Sch Neurosci, Tel Aviv, Israel

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR-017

引用

页码：181 / 181

页数：1

共 50 条

[21] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
Adar, L.
Vostokova, N.
MOVEMENT DISORDERS, 2022, 37 : S438 - S439
[22] Continuous Subcutaneous Levodopa/Carbidopa Infusion With ND0612 For Patients With Parkinson's Disease And Motor Fluctuations: Results From The Phase 3 Randomized, Active-Controlled BouNDless Study
Rascol, O.
Albanese, A.
Ellenbogen, A.
Ferreira, J.
Giladi, N.
Gurevich, T.
Hassin-Baer, S.
Hernandez-Vara, J.
Isaacson, S.
Kieburtz, K.
LeWitt, P.
Lopez-Manzanares, L.
Olanow, C. W.
Pahwa, R.
Poewe, W.
Sarva, H.
Stocchi, F.
Yardeni, T.
Adar, L.
Salin, L.
Lopes, N.
Sasson, N.
Case, R.
Espay, A.
MOVEMENT DISORDERS, 2023, 38 : S4 - S4
[23] Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of Parkinson's disease (PD) and Experiences of Daily Living
Rascol, O.
Isaacson, S.
LeWitt, P.
Poewe, W.
Ferreira, J.
Lopes, N.
Sopromadze, S.
Pereira, J.
Olanow, C.
MOVEMENT DISORDERS, 2024, 39 : S313 - S313
[24] Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD
Olanow, W.
Ellenbogen, A.
Djaldetti, R.
Minei, T. Rachmilewitz
Cohen, Y.
Oren, S.
Kieburtz, K.
MOVEMENT DISORDERS, 2017, 32
[25] Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day
Ellenbogen, A.
Ferreira, J.
Stocchi, F.
Kieburtz, K.
Albanese, A.
Adar, L.
Vostokova, N.
Pereira, J.
Hauser, R.
MOVEMENT DISORDERS, 2024, 39 : S312 - S313
[26] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION (ND0612) FOR PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS: A PHASE 3, ACTIVE-CONTROLLED STUDY (BOUNDLESS)
Stocchi, F.
Espay, A.
Albanese, A.
Ellenbogen, A.
Ferreira, J. J.
Giladi, N.
Gurevich, T.
Hassin-Baer, S.
Hernandez-Vara, J.
Isaacson, S.
Kieburtz, K.
LeWitt, P.
Lopez-Manzanares, L.
Olanow, C. W.
Pahwa, R.
Poewe, W.
Sarva, H.
Yardeni, T.
Adar, L.
Lopes, N.
Sasson, N.
Case, R.
Rascol, O.
PARKINSONISM & RELATED DISORDERS, 2024, 122
[27] The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson's disease
Poewe, W.
Stocchi, F.
Espay, A.
Minei, T. Rachmilewitz
Oren, S.
Case, R.
Kieburtz, K.
Olanow, C.
MOVEMENT DISORDERS, 2018, 33 : S131 - S132
[28] The BeyoND study: design and baseline characteristics of an international, multicentre study evaluating the long-term safety of ND0612 for Parkinson's disease
Poewe, W.
Stocchi, F.
Espay, A.
Oren, S.
Durlach, C.
Kieburtz, K.
Olanow, C.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 154 - 154
[29] ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Giladi, N.
Caraco, Y.
Gurevich, T.
Djaldetti, R.
Adar, L.
Minei, T. Rachmilewitz
Oren, S.
MOVEMENT DISORDERS, 2017, 32
[30] First Results for The BeyoND Study: An open-label international, multicenter study evaluating the long-term safety of ND0612 in patients with idiopathic Parkinson's disease
Isaacson, Stuart
Poewe, Werner
Simuni, Tanya
Oren, Sheila
Case, Ryan
Olanow, C. Warren
NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →